Showing results (1981-1990 of 2,338) with videos related to

Sort By:
Pageof 234
European Journal of Cancer (Oxford, England : 1990)|September 6, 2003
Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II studyJ Verweij, A van Oosterom, J-Y Blay, et al.
The American Journal of Pathology|February 5, 2008
A role for the receptor for advanced glycation end products in idiopathic pulmonary fibrosisJudson M Englert, Lana E Hanford, Naftali Kaminski, et al.
Biorxiv : the Preprint Server for Biology|July 16, 2025
Characterization of the BRAF interactome identifies BRAF V600E TP53 interaction in melanomaKayla T O'Toole, Adamaris Martinez, Brandon Murphy, et al.
British Journal of Cancer|September 8, 2023
Axitinib in patients with advanced/metastatic soft tissue sarcoma (Axi-STS): an open-label, multicentre, phase II trial in four histological strataPenella J Woll, Piers Gaunt, Charlotte Gaskell, et al.
Neuron|March 30, 2016
GABAergic Neuron-Specific Loss of Ube3a Causes Angelman Syndrome-Like EEG Abnormalities and Enhances Seizure SusceptibilityMatthew C Judson, Michael L Wallace, Michael S Sidorov, et al.
Scientific Data|December 12, 2018
The metabolic regimes of 356 rivers in the United StatesAlison P Appling, Jordan S Read, Luke A Winslow, et al.
Gynecologic Oncology|October 29, 2011
The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatinHye Sook Chon, Douglas C Marchion, Yin Xiong, et al.
Cancer Research|October 20, 2004
A gene expression signature associated with metastatic outcome in human leiomyosarcomasYin-Fai Lee, Megan John, Alison Falconer, et al.
Neuroimage|May 21, 2013
Real-time fMRI links subjective experience with brain activity during focused attentionKathleen A Garrison, Dustin Scheinost, Patrick D Worhunsky, et al.
Cancer|June 3, 2015
Health-related quality-of-life results from PALETTE: A randomized, double-blind, phase 3 trial of pazopanib versus placebo in patients with soft tissue sarcoma whose disease has progressed during or after prior chemotherapy-a European Organization for research and treatment of cancer soft tissue and bone sarcoma group global network study (EORTC 62072)Corneel Coens, Winette T A van der Graaf, Jean-Yves Blay, et al.
Pageof 234